These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

543 related articles for article (PubMed ID: 22752507)

  • 21. Post-surgery adjuvant therapy with intermediate doses of interferon alfa 2b versus observation in patients with stage IIb/III melanoma (EORTC 18952): randomised controlled trial.
    Eggermont AM; Suciu S; MacKie R; Ruka W; Testori A; Kruit W; Punt CJ; Delauney M; Sales F; Groenewegen G; Ruiter DJ; Jagiello I; Stoitchkov K; Keilholz U; Lienard D;
    Lancet; 2005 Oct; 366(9492):1189-96. PubMed ID: 16198768
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Temozolomide plus pegylated interferon alfa-2b as first-line treatment for stage IV melanoma: a multicenter phase II trial of the Dermatologic Cooperative Oncology Group (DeCOG).
    Spieth K; Kaufmann R; Dummer R; Garbe C; Becker JC; Hauschild A; Tilgen W; Ugurel S; Beyeler M; Bröcker EB; Kaehler KC; Pföhler C; Gille J; Leiter U; Schadendorf D
    Ann Oncol; 2008 Apr; 19(4):801-6. PubMed ID: 18178958
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Adjuvant therapy of melanoma: is pegylated interferon alfa-2b what we've been waiting for?
    Sondak VK; Flaherty LE
    Lancet; 2008 Jul; 372(9633):89-90. PubMed ID: 18620932
    [No Abstract]   [Full Text] [Related]  

  • 24. High-dose interferon alfa-2b significantly prolongs relapse-free and overall survival compared with the GM2-KLH/QS-21 vaccine in patients with resected stage IIB-III melanoma: results of intergroup trial E1694/S9512/C509801.
    Kirkwood JM; Ibrahim JG; Sosman JA; Sondak VK; Agarwala SS; Ernstoff MS; Rao U
    J Clin Oncol; 2001 May; 19(9):2370-80. PubMed ID: 11331315
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Checkpoint inhibitors: the new treatment paradigm for urothelial bladder cancer.
    Katz H; Wassie E; Alsharedi M
    Med Oncol; 2017 Sep; 34(10):170. PubMed ID: 28864844
    [TBL] [Abstract][Full Text] [Related]  

  • 26. INFα-2b inhibitory effects on CD4(+)CD25(+)FOXP3(+) regulatory T cells in the tumor microenvironment of C57BL/6 J mice with melanoma xenografts.
    Yu Y; Huang R; Zong X; He X; Mo W
    BMC Cancer; 2016 Jul; 16():397. PubMed ID: 27389040
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Effects of high-dose IFNalpha2b on regional lymph node metastases of human melanoma: modulation of STAT5, FOXP3, and IL-17.
    Wang W; Edington HD; Rao UN; Jukic DM; Radfar A; Wang H; Kirkwood JM
    Clin Cancer Res; 2008 Dec; 14(24):8314-20. PubMed ID: 19088050
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Developing indications for the use of sentinel lymph node biopsy and adjuvant high-dose interferon alfa-2b in melanoma.
    Dubois RW; Swetter SM; Atkins M; McMasters K; Halbert R; Miller SJ; Shiell R; Kirkwood J
    Arch Dermatol; 2001 Sep; 137(9):1217-24. PubMed ID: 11559220
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Efficacy, safety, and risk-benefit analysis of adjuvant interferon alfa-2b in melanoma.
    Kirkwood JM; Resnick GD; Cole BF
    Semin Oncol; 1997 Feb; 24(1 Suppl 4):S16-23. PubMed ID: 9122729
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Neoadjuvant Pembrolizumab and High-Dose IFNα-2b in Resectable Regionally Advanced Melanoma.
    Najjar YG; McCurry D; Lin H; Lin Y; Zang Y; Davar D; Karunamurthy A; Drabick JJ; Neves RI; Butterfield LH; Ernstoff MS; Puzanov I; Skitzki JJ; Bordeaux J; Summit IB; Bender JO; Kim JY; Chen B; Sarikonda G; Pahuja A; Tsau J; Alfonso Z; Laing C; Pingpank JF; Holtzman MP; Sander C; Rose A; Zarour HM; Kirkwood JM; Tarhini AA
    Clin Cancer Res; 2021 Aug; 27(15):4195-4204. PubMed ID: 33753453
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Adjuvant therapy for resected stage III melanoma patients: high-dose interferon-alpha versus ipilimumab combined with kinases inhibitors.
    Minutilli E; Feliciani C
    Tumori; 2012; 98(2):185-90. PubMed ID: 22677983
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Intravenous high-dose interferon with or without maintenance treatment in melanoma at high risk of recurrence: meta-analysis of three trials.
    Malczewski A; Marshall A; Payne MJ; Mao L; Bafaloukos D; Si L; Pectasides D; Fountzilas G; Guo J; Gogas H; Middleton MR
    Cancer Med; 2016 Jan; 5(1):17-23. PubMed ID: 26645567
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Prospective randomized trial of interferon alfa-2b and interleukin-2 as adjuvant treatment for resected intermediate- and high-risk primary melanoma without clinically detectable node metastasis.
    Hauschild A; Weichenthal M; Balda BR; Becker JC; Wolff HH; Tilgen W; Schulte KW; Ring J; Schadendorf D; Lischner S; Burg G; Dummer R
    J Clin Oncol; 2003 Aug; 21(15):2883-8. PubMed ID: 12885805
    [TBL] [Abstract][Full Text] [Related]  

  • 34. U.S. Food and Drug Administration Approval: peginterferon-alfa-2b for the adjuvant treatment of patients with melanoma.
    Herndon TM; Demko SG; Jiang X; He K; Gootenberg JE; Cohen MH; Keegan P; Pazdur R
    Oncologist; 2012; 17(10):1323-8. PubMed ID: 23002124
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Phase III trial comparing adjuvant treatment with pegylated interferon Alfa-2b versus observation: prognostic significance of autoantibodies--EORTC 18991.
    Bouwhuis MG; Suciu S; Testori A; Kruit WH; Salès F; Patel P; Punt CJ; Santinami M; Spatz A; Ten Hagen TL; Eggermont AM
    J Clin Oncol; 2010 May; 28(14):2460-6. PubMed ID: 20385998
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Intermittent High-Dose Intravenous Interferon Alfa-2b for Adjuvant Treatment of Stage III Melanoma: Final Analysis of a Randomized Phase III Dermatologic Cooperative Oncology Group Trial.
    Mohr P; Hauschild A; Trefzer U; Enk A; Tilgen W; Loquai C; Gogas H; Haalck T; Koller J; Dummer R; Gutzmer R; Brockmeyer N; Hölzle E; Sunderkötter C; Mauch C; Stein A; Schneider LA; Podda M; Göppner D; Schadendorf D; Weichenthal M
    J Clin Oncol; 2015 Dec; 33(34):4077-84. PubMed ID: 26503196
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Health-related quality of life in patients with high-risk melanoma randomised in the Nordic phase 3 trial with adjuvant intermediate-dose interferon alfa-2b.
    Brandberg Y; Aamdal S; Bastholt L; Hernberg M; Stierner U; von der Maase H; Hansson J
    Eur J Cancer; 2012 Sep; 48(13):2012-9. PubMed ID: 22196968
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Randomized phase III study of 1 month versus 1 year of adjuvant high-dose interferon alfa-2b in patients with resected high-risk melanoma.
    Pectasides D; Dafni U; Bafaloukos D; Skarlos D; Polyzos A; Tsoutsos D; Kalofonos H; Fountzilas G; Panagiotou P; Kokkalis G; Papadopoulos O; Castana O; Papadopoulos S; Stavrinidis E; Vourli G; Ioannovich J; Gogas H
    J Clin Oncol; 2009 Feb; 27(6):939-44. PubMed ID: 19139440
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Serum concentrations of pegylated interferon alpha-2b in patients with resected stage III melanoma receiving adjuvant pegylated interferon alpha-2b in a randomized phase III trial (EORTC 18991).
    Eggermont AM; Bouwhuis MG; Kruit WH; Testori A; ten Hagen T; Yver A; Xu C
    Cancer Chemother Pharmacol; 2010 Mar; 65(4):671-7. PubMed ID: 19621225
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Phase III Study of Adjuvant Ipilimumab (3 or 10 mg/kg) Versus High-Dose Interferon Alfa-2b for Resected High-Risk Melanoma: North American Intergroup E1609.
    Tarhini AA; Lee SJ; Hodi FS; Rao UNM; Cohen GI; Hamid O; Hutchins LF; Sosman JA; Kluger HM; Eroglu Z; Koon HB; Lawrence DP; Kendra KL; Minor DR; Lee CB; Albertini MR; Flaherty LE; Petrella TM; Streicher H; Sondak VK; Kirkwood JM
    J Clin Oncol; 2020 Feb; 38(6):567-575. PubMed ID: 31880964
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 28.